Review assesses advancements in green synthesis methods for active pharmaceutical ingredients, highlighting efficiency and sustainability.
Introduction: Green chemistry offers a paradigm shift in pharmaceutical manufacture by fusing efficiency, sustainability, and regulatory compliance. This review work is an effort to assess the developments in green synthetic pathways for APIs, along with focusing on measurements, technologies, and industrial case studies that exhibit sustainability without sacrificing efficiency. Methods: An analysis of industry data and literature focused on the following topics: atom economics, E-factor, process mass intensity, lifetime evaluation, and eco-scale. Results: Traditional pathways were routinely outperformed by green ones. One example of how biocatalysis was used to eliminate waste and heavy metals is sitagliptin. While improvements in solvents, like deep eutectic solvents and bio-based substitutes, reduced their negative effects on the environment, continuous flow enhanced PMI, safety, and reproducibility. Mechanochemical methods enabled solvent-free synthesis, and circular economy concepts were integrated into renewable feedstocks. Discussion: Rather than being a small improvement, these advances represent a significant boost in sustainable pharmaceutical manufacture. Despite ongoing problems with regulatory frameworks, catalyst accessibility, and scale-up, the improvements in overall efficiency, operational safety, and waste reduction show the value and industrial significance of these technologies. Conclusions: Green chemistry is currently the foundation of next-generation pharmaceutical production since green synthesis techniques for APIs have progressed from theory to practical application.
No takes yet. Share an insight, caveat, or question.
Sangal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: